NTG

Notogen is a pre-clinical biotechnology company dedicated to developing regenerative therapeutics for spinal pain and musculoskeletal degeneration. The company's lead candidate, NTG-101, is a first-in-class, non-cellular molecular therapy designed to treat degenerative disc disease (DDD) by inducing disc regeneration and resolving discogenic pain. NTG-101 is a protein-based biologic administered via a single intradiscal injection, containing a proprietary combination of recombinant human transforming growth factor beta 1 and connective tissue growth factor. Notogen's approach leverages over 20 years of research into notochordal cell biology to provide a non-surgical alternative for millions of patients suffering from chronic back and neck dysfunction.